Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • News

Driving Change in Oncology: Pivotal Data and Global Trends at #ASCO25

  • The Pharma Data
  • May 27, 2025

Practice-Changing Data, Innovative Modalities, and Global Impact Headline ASCO 2025 The oncology community is converging in Chicago this week for the highly anticipated 2025 Annual Meeting of the American Society…

Read MoreDriving Change in Oncology: Pivotal Data and Global Trends at #ASCO25
  • News

4 Biotech Firms Face Hurdles Amid a Shifting COVID-19 Vaccine Landscape

  • The Pharma Data
  • May 27, 2025

U.S. Vaccine Innovation at Risk: How Four Biotechs Are Being Squeezed by Shifting Policies, Funding Cuts, and Regulatory Changes As the World Health Organization (WHO) sets a new course for…

Read More4 Biotech Firms Face Hurdles Amid a Shifting COVID-19 Vaccine Landscape
  • News

World Health Assembly Extends Global Digital Health Strategy to 2027, Approves 2028–2033 Phase

  • The Pharma Data
  • May 24, 2025

World Health Assembly Approves Extension of Global Digital Health Strategy to 2027 and Greenlights Next Phase for 2028–2033 In a landmark decision underscoring the accelerating global commitment to digital health,…

Read MoreWorld Health Assembly Extends Global Digital Health Strategy to 2027, Approves 2028–2033 Phase
  • Press Releases

Cullinan, Taiho to Present Positive Zipalertinib Phase 2b Results at ASCO 2025

  • The Pharma Data
  • May 24, 2025

Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S.…

Read MoreCullinan, Taiho to Present Positive Zipalertinib Phase 2b Results at ASCO 2025
  • News

XTANDI Delivers Long-Term Survival in Metastatic Hormone-Sensitive Prostate Cancer

  • The Pharma Data
  • May 24, 2025

Astellas and Pfizer Showcase Five-Year Survival Benefits of XTANDI in Metastatic Hormone-Sensitive Prostate Cancer at ASCO 2025 In a pivotal milestone for prostate cancer treatment, Astellas Pharma Inc. and Pfizer…

Read MoreXTANDI Delivers Long-Term Survival in Metastatic Hormone-Sensitive Prostate Cancer
  • News

Walgreens Clinical Trials: 3 Strategies for Patient-Centered Engagement

  • The Pharma Data
  • May 24, 2025

Bringing Research to the People: How Walgreens Clinical Trials is Revolutionizing Patient Engagement Over the past three years, Walgreens has made remarkable strides in democratizing access to clinical trials. Through…

Read MoreWalgreens Clinical Trials: 3 Strategies for Patient-Centered Engagement
  • News

Court Blocks HHS Layoff and Restructuring Plans, Citing Overreach of Authority

  • The Pharma Data
  • May 24, 2025

Federal Judge Blocks Trump Administration’s Sweeping HHS Layoff and Reorganization Plan, Citing Lack of Legal Authority A federal judge in California has issued a significant legal blow to the Trump…

Read MoreCourt Blocks HHS Layoff and Restructuring Plans, Citing Overreach of Authority
  • News

EU Recommends Approval of Eylea™ 8 mg with Extended 6-Month Dosing Interval

  • The Pharma Data
  • May 24, 2025

Bayer’s Eylea™ 8 mg Recommended for EU Approval with Extended 6-Month Treatment Interval for Major Retinal Diseases Bayer has today announced a significant milestone in the treatment of retinal diseases,…

Read MoreEU Recommends Approval of Eylea™ 8 mg with Extended 6-Month Dosing Interval
  • News

CHMP Backs Blenrep Combos for Relapsed/Refractory Multiple Myeloma

  • The Pharma Data
  • May 24, 2025

GSK’s Blenrep Combinations Receive Positive CHMP Opinion for Relapsed or Refractory Multiple Myeloma, Signaling Expanded Access Across Europe In a significant step forward for the treatment of multiple myeloma, GSK…

Read MoreCHMP Backs Blenrep Combos for Relapsed/Refractory Multiple Myeloma
  • News

NICE in England Recommends FILSPARI for the Treatment of IgA Nephropathy

  • The Pharma Data
  • May 24, 2025

NICE Recommends FILSPARI® (sparsentan) for Routine Use in the NHS to Treat Adults with IgA Nephropathy, Marking a Significant Step Forward in Rare Kidney Disease Management CSL Vifor has announced…

Read MoreNICE in England Recommends FILSPARI for the Treatment of IgA Nephropathy
  • News

CVS Health Survey Reveals Smoking Trends Among Young Adults

  • The Pharma Data
  • May 24, 2025

Rethinking Nicotine: CVS Health Survey Uncovers Widespread Misconceptions About E-Cigarette Safety Among Young Adults Over the past few decades, the public conversation around tobacco and nicotine use has transformed dramatically.…

Read MoreCVS Health Survey Reveals Smoking Trends Among Young Adults
  • News

ASCENT-03: Trodelvy Significantly Improves PFS in First-Line mTNBC Patients Ineligible for Checkpoint Inhibitors

  • The Pharma Data
  • May 24, 2025

Trodelvy Marks Breakthrough in First-Line mTNBC Treatment with Positive Phase 3 ASCENT-03 Results Gilead Sciences has announced encouraging topline results from its Phase 3 ASCENT-03 clinical trial evaluating Trodelvy® (sacituzumab…

Read MoreASCENT-03: Trodelvy Significantly Improves PFS in First-Line mTNBC Patients Ineligible for Checkpoint Inhibitors
PrevNext
UK Biotech Day
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial for Manganese MRI Contrast Agent
  • Ironwood Pharmaceuticals to Present HCP Insights on TPN Burden in Short Bowel Syndrome at Digestive Disease Week® 2026
  • Bausch + Lomb Publishes Review on B Vitamins and AMD Risk Reduction
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.